β-strand mimicking macrocyclic amino acids: Templates for protease inhibitors with antiviral activity

Journal of Medicinal Chemistry

Volumn 45, Issue 2, 2002, Pages 371-381

  Glenn, Matthew P ^a   Pattenden, Leonard K ^a   Reid, Robert C ^a   Tyssen, David P ^b   Tyndall, Joel D A ^a   Birch, Christopher J ^b   Fairlie, David P ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO N (2 AMINO ISOPROPYL 8,11 DIOXO 2 OXA 9,12 DIAZABICYCLO[13.2.2]NONADECA 1(18),15(19),16 TRIEN YL) HYDROXY ETHYL] N (3 METHYLBUTYL)BENZENESULFONAMIDE; [2 [(4 ACETYLAMINO BENZENESULFONYL) (3 METHYLBUTYL)AMINO]HYDROXYETHYL]BUTYL 8,11 DIOXO 2 OXA 9,12 DIAZABICYCLO[13.2.2]NONADECA 1(18),15(19),16 TRIEN YLCARBAMIC ACID TERT BUTYL ESTER; AMINO ACID DERIVATIVE; ISOLEUCINE; MACROCYCLIC COMPOUND; PENTANOIC ACID [2 [(4 AMINO BENZENESULFONYL) (3 METHYLBUTYL)AMINO]HYDROXYETHYL]BUTYL 8,11 DIOXO 2 OXA 9,12 DIAZABICYCLO[13.2.2.]NONADECA 1(18),15(19),16 TRIEN YLAMIDE; PHENYLALANINE; PROTEINASE INHIBITOR; TYROSINE; UNCLASSIFIED DRUG; VALINE;

AMINO ACID ANALYSIS; AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; DRUG CONFORMATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; INHIBITION KINETICS; LIPOPHILICITY; MEMBRANE PERMEABILITY; MOLECULAR MIMICRY; PROTEIN CONFORMATION; PROTEINASE INHIBITION; RECEPTOR AFFINITY; VIRUS REPLICATION;

AMINO ACIDS; ANTI-HIV AGENTS; CELL LINE; CYTOPATHOGENIC EFFECT, VIRAL; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MODELS, MOLECULAR; OLIGOPEPTIDES; PEPTIDES, CYCLIC; PROTEIN STRUCTURE, SECONDARY;

EID: 0037122707     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm010414i     Document Type: Article

References (37)

1. High-throughput X-ray crystallography for structure-based drug design
2. "Flu" and structure-based drug design
3. Protein targets for structure-based drug design
4. Molecular recognition of protein - Ligand complexes: Applications to drug design
5. Protease inhibitors: Current status and future prospects
6. HIV protease as an inhibitor target for the treatment of AIDS
7. Targeting HIV-1 protease: A test of drug-design methodologies
8. HIV protease inhibitors
9. Therapeutic advances: Protease inhibitors for the treatment of HIV-1 infection
10. Inhibitors of HIV-1 protease: A major success of structure-assisted drug design
11. Approaches to the design of effective HIV-1 protease inhibitors
12. The next generation of human immunodeficiency virus protease inhibitors: Targeting viral resistance
13. Conformational homogeneity in molecular recognition by proteolytic enzymes
14. Conformational selection of inhibitors and substrates by proteolytic enzymes: Implications for drug design and polypeptide processing
15. Regioselective structural and functional mimicry of peptides: Design of hydrolytically stable cyclic peptidomimetic inhibitors of HIV 1 protease
16. Substrate based cyclic peptidomimetics of PheIleVal that inhibit HIIV-1 protease using a novel enzyme binding mode
17. Structure - Activity relationships for macrocyclic inhibitors of HIV-1 protease
18. A novel bicyclic enzyme inhibitor as a consensus peptidomimetic for the receptor-bound conformations of 12 peptidic inhibitors of HIV-1 protease
19. Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease
20. Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease
21. Macrocycles mimic the extended peptide conformation recognized by aspartic, serine, cysteine and metallo proteases
22. X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor
23. Template forcing minimises the RMSD using a specific minimisation algorithm that allows rotation around single bonds as well as translation and rotation in space
24. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
25. The not so great escape
26. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development
27. Collagen cross-links: Synthesis of pyridinonline, deoxypyridinoline and their analogues
28. Kinetic-properties of HIV-1 protease produced by total chemical synthesis with cysteine residues replaced by isosteric l-alpha-amino-n-butyric acid
29. A simple, continuous fluorometric assay for HIV protease
30. Crystal structure of HIV-1 protease in complex with VX478, a potent and orally bioavailable inhibitor of the enzyme
31. Enzymatic activity of a synthetic 99 residue protein corresponding to the putative HIV-1 protease
32. Isolation of HIV from Australian patients with AIDS, AIDS related conditions and healthy antibody positive individuals
33. Investigation of topoisomerase inhibitors for activity against human immunodeficiency virus: Inhibition by coumermycin A1